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Management of minimal lesion glomerulonephritis: Evidence- investigators include staining with IgM, and there may
based recommendations. The treatment of idiopathic minimal be a spectrum of disease between minimal lesion and
lesion disease in children has been extensively studied in ran- IgM mesangial proliferative glomerulonephritis. Indeed,domized controlled trials, however, there is less information
this is a potential cause of confusion because some stud-available for adults. This article summarizes evidence-based
ies allow mesangial proliferation and/or staining withrecommendations for management. The first attack should be
treated with prednisone or prednisolone at 60 mg/m2 per day IgM as a variant of minimal lesion, whereas others do
(up to a maximum of 80 mg/day) for four to six weeks, followed not. Although deposition of IgM does not appear to
by 40 mg/m2 of prednisone every other day for another four change prognosis, mesangial hypercellularity is associ-to six weeks (grade A). Relapse should be treated with 60 mg/
ated with late nonresponse [5]. Others have not found anm2/day of prednisone (up to 80 mg/day) only until the urine
association between histology and postbiopsy course [6].becomes protein free for three days, and then an alternate day
regimen of 40 mg/m2 should be used for another month (grade
A). Patients with frequently relapsing disease will have a sig- Methods
nificant reduction in relapse frequency after eight weeks of an
The evidence used in compiling these recommenda-alkylating agent (grade A). Less rigorous studies have sug-
tions was obtained from published trials found in a MED-gested benefit with long-term, alternate-day corticosteroid
(grade D) or the antihelminthic agent levamisole (grade D). LINE search of the English language literature. Second-
For patients with steroid-dependent disease, an 8- or 12-week ary references from the bibliography of the initial studies
course with cyclophosphamide can induce remission (grade were also perused, as were personal files. Recommenda-D). In true steroid-resistant disease, observational studies have
tions were graded from A to D, based on the level ofsuggested that a course of cyclosporine may sometimes induce
evidence of the supporting studies.remission or restore steroid responsiveness (grade D). Large
retrospective studies in adults suggest that therapeutic response
is slower than in children, but adults experience fewer relapses
and more prolonged remission. TREATMENT OF MINIMAL LESION
GLOMERULONEPHRITIS IN CHILDREN
Tables 1, 2, and 3 review the levels of evidence of
Minimal lesion glomerulonephritis typically presents English language studies in children.
with the acute onset of nephrotic syndrome, often follow-
ing a viral upper respiratory tract infection. Complica- Treatment of the first attack
tions include thrombosis, acute renal failure, and infec- Recommendation 1. Prednisone at 60 mg/m2 per day
tions such as cellulitis, peritonitis, and pneumonia [1]. (up to a maximum of 80 mg/day) for four to six weeks
Older literature suggests that spontaneous remissions (grade A) and then 40 mg/m2 of prednisone every other
occur in children with minimal lesion disease, usually day for four to six weeks (grade A) are recommended.
after many months of disease compared with a much Evidence. Minimal lesion accounts for more than 90%
earlier remission time induced with corticosteroids [2–4]. of cases of idiopathic nephrotic syndrome in young chil-
Histology demonstrates essentially normal-appearing dren. Uncontrolled studies in the 1950s demonstrated
glomeruli on light microscopy, although there may be that more than 90% of children would respond to corti-
some expansion of the mesangial matrix. Immunofluo- costeroid treatment. The pioneering studies of the Inter-
rescence is usually negative for immunoglobulins. Some national Study of Kidney Diseases in Children (ISKDC)
settled on a regimen of 60 mg/m2/day prednisone, to
a maximum of 80 mg/day for four weeks, followed byKey words: prednisone, prednisolone, nephrotic syndrome, acute renal
failure, corticosteroids. intermittent prednisone (40 mg/m2/day) on three consec-
utive days out of seven days for the next four weeks [7]. 1999 by the International Society of Nephrology
S-3
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Table 1. Corticosteroids in children, level 1 or 2
Author [Ref] Study design N Treatment Results/comments
APN [8] RCT frequent relapsers in 25 intermittent Remission induced with daily Pred, 72% relapse in first 6 months
remission to Pred for then Pred 40 mg/m2 for 3/7 days (intermittent)
3/7 days or alt days or 35 mg/m2q alt day; 6 months
total
24 alt day 43% relapse in first 6 months
(alt day)
Relapse rate similar after that
ISKDC [14] Children with early 26 shorter Shorter: 60 mg Pred until CR (avg Shorter: 40% relapsed during
relapse randomized to 12 days) then 40 mg 3/7 days 3 treatment protocol
shorter vs. longer Pred 4 weeks
regimens
28 longer Longer: 60 mg Pred/day 3 4 weeks Longer: 8% relapsed during
then 40 mg/day 3 1 week, 30 treatment protocol
mg/day 3 1 week, etc. All patients relapsed by 8
months
Longer group had 2 3 Pred
APN [11] Children with first attack 32 shorter Shorter: Pred 60 mg/m2 until CR 3 Shorter course used 50% less
randomized to shorter 3 day, then 40 mg/m2 q 48 hr Pred but twice the relapse
vs. longer courses of until serum alb $35 g/liter rate, half the relapse free
Pred interval
29 longer Longer: Pred 60 mg/m2/day 3 4 Total Pred including relapse
weeks then 40 mg/m2 q 48 hr 3 rx similar – no advantage
4 weeks to shorter regimen
Ueda [13] Children with first attack 29 shorter Shorter: Pred 60 mg/m2/day 3 4 Longer regimen had less
randomized to shorter weeks, then 40 mg/m2/day 3/7 relapses while on
vs. longer courses of days 3 4 weeks treatment, so total amount
Pred of Pred did not differ
between 2 groups
17 longer Longer: Pred 60 mg/m2/day 3 4 Longer regimen had fewer
weeks, then 60 mg/m2/alt day 3 patients who became
4 weeks, then tapered over 5 steroid dependent or
months frequent relapsers
Ehrich [12] Children with first attack 37 shorter Shorter: 60 mg/day 3 4 weeks then Longer treatment patients
randomized to shorter 40/mg/m2 q 48 hr 3 4 weeks more likely to remain in
vs. longer courses of 34 longer Longer: 60 mg/m2/day 3 6 weeks, remission, less frequent
Pred then 40 mg/m2 q 48 hr 3 6 weeks relapsers in longer
treatment group
Total Pred dose at one year
similar in both groups
Abbreviations are: alt, alternate; APN, Arbeitsgemeinschaft fur Padiatrische Nephrologie; ARF, acute renal failure; AZA, azathioprine; Chloram, chlorambucil;
CR, complete remission; CTX, cyclophosphamide; CsA, cyclosporine; F/U, follow-up; ISKDC, International Study of Kidney Disease in Children; ML, minimal
lesion; NS, nephrotic syndrome; PR, partial remission; Pred, prednisone or prednisolone; RCT, randomized controlled trial; stat sign, statistically significant; VAR,
variable.
The European collaborative group, Arbeitsgemein- a shorter course of initial treatment might be just as
effective as the standard regimen. The APN performedschaft fur Padiatrische Nephrologie (APN), suggested
that in the second four weeks of treatment, prednisone a randomized controlled study of their standard regimen
(four weeks of daily prednisone plus four weeks of alter-given every second day might be more effective in pre-
venting relapses. These two regimens were compared in nate-day prednisone) compared with a short-course
group who received 60 mg/m2/day of prednisone untila randomized controlled study in a group of 48 frequently
relapsing patients [8]. Patients receiving alternate-day the urine was clear of protein (about two weeks) and then
took alternate-day prednisone until the serum albuminprednisone had an approximate 50% reduction in re-
lapse rate compared with the controls receiving predni- normalized (another two weeks). Although the short-
course group initially received only half of the amountsone three days out of seven. This difference occurred
during only the six months of the trial, whereas the later of prednisone, they relapsed twice as often and twice as
soon, and ultimately received as much steroid as therelapse rate was similar. The investigators concluded that
the alternate-day regimen was superior for the second standard treatment group [11]. The authors concluded
that there was no benefit to the shorter therapy.four weeks of therapy and have recommended it even
for the first attack of minimal lesion disease [9]. Several years later, they examined whether longer ini-
tial therapy conferred added protection against relapseMost patients will clear their proteinuria by two weeks
of therapy [10]. Investigators have questioned whether [12]. Here, children with a first attack were randomly
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Table 2. Alkylating and antimetabolite agents in children
Author [Ref] Study design N Treatment Results/comments
Level 1 or 2
Abramozicz [18] RCT of 197 children rx 38 nonresponders Pred 1 AZA or placebo 3 3 months No difference AZA from
Pred 8 weeks placebo
49 frequent relapsers Pred 1 AZA or placebo 3 6 months Trend to less relapses in AZA
group but not stat sig
Barratt [19] RCT of Pred vs. Pred 10 Pred Pred taper over 8 weeks 9/10 relapsed by one year
1 CTX in 10 Pred 1 CTX “maintenance” Pred 1 CTX 3 mg/ 2/10 relapsed by one year
frequently relapsing kg/day over 8 weeks then Pred (P,0.05)
NS, in remission taper over 8 weeks
Barratt [20] RCT of Pred and either 16 CTX 2 weeks “Maintenance” Pred over 8 weeks, 9/16 relapsed by weeks 24
2 or 8 weeks of CTX taper over 8 weeks 1 CTX 3 mg/
in frequently kg/day 3 2 weeks
relapsing NS, in 16 CTX 8 weeks Same except CTX 3 8 weeks 1/16 relapsed by week 24
remission (P,0.05)
ISKDC [21] RCT “early non- 33 of which 15 Prd Intermittent Pred 6 CTX (var dose) (not all had ML)
responders” (at 8 alone 3 90 days Pred alone: 40% CR by 95
weeks of Pred) to 18 Pred 1 CTX days.
intermittent Pred Pred 1 CTX: 56% CR by 38
alone or with CTX days
RCT frequent 53 of which 26 Pred Intermittent Pred 6 CTX (var dose) Pred alone: 88% relapse by
relapsers alone 3 42 days mean 22 months
intermittend Pred 27 Pred 1 CTX Pred 6 CTX: 48% relapse
alone or with CTX
Grupe [23] Steroid-dependent or 11 Pred alone All chlorambucil patients went
frequently relapsing into CR for full F/U (mean
NS 19.6 months) vs. all 11 on
RCT Pred alone or Pred had recurrent NS by
Pred 1 7 months
chlorambucil 10 Pred 1 Chloram 0.1–0.2 mg/kg/day in
chlorambucil divided doses, titrated to WBC 3
6–12 weeks total
APN [17] Frequently relapsing or 2 3 2: After remission, randomized to CTX or chloram decreased
steroid-dependent 16 frequent chloramb 0.15 mg/kg/day 3 56 relapse rate in frequent
RCT to Pred 1 relapsers 8 days along with alt day Pred relapsers
chloramb or to Pred chloramb, 8 CTX or
1 CTX
34 steroid dependent CTX 2 mg/kg/day 3 56 days along No difference in time to
16 chloram, 18 with alt day Pred relapse in steroid
CTX dependent group
No difference CTX vs.
chloramb (small#’s)
Ueda [26] Steroid-dependent 32 CTX 3 8 weeks After remission, CTX 2 mg/kg/day 3 No difference 8 vs. 12 weeks
RCT to CTX for 8 8 weeks or CTX 2 mg/kg/day 3 rx (compare with APN
or 12 weeks 41 CTX 3 12 weeks 12 weeks 1987 below)
Level 3 or 4
Chiu [29] Frequent relapsers rx 36 Pred 1 CTX CTX 75 mg/m2/day 1 Pred 60 mg/m2/ 33% relapse by mean 4 year
Pred and CTX day then tapered; duration 4 months F/U
compared with
historical controls
Pred alone 11 Pred alone Hist controls: Pred same regimen 3 91% relapse by mean 2 year
4 months F/U
Barratt [22] Follow up 1973 study of 82 CTX CTX 3 mg/kg/day (most also received Remission lasted longer in
frequent relapsers Pred) 3 8 weeks older children; better
outcome if in CR at onset of
CTX rx
Pennisi [30] Steroid-dependent NS 29 6–8 week CTX CTX 3–5 mg/kg/day 3 6–8 weeks 1 42% relapse rate at one year;
treated with alt day alt day Pred 21% still in CR at 3.5 years
Pred and 6–8 or 12 24 12 week CTX CTX 3–5 mg/kg/day 3 12 weeks 1 8% relapse rate at one year;
weeks CTX; retro- alt day Pred 63% still in CR at 3.5 years
spective analysis
(Continued)
allocated to a long treatment consisting of daily predni- undergoing the standard regimen. This level 1 study dem-
onstrated that the long-treatment patients were twice assone for six weeks and alternate-day prednisone for six
weeks, and the children were then compared with those likely to remain in remission compared with the patients
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Table 2. (Continued)
Author [Ref] Study design N Treatment Results/comments
Williams [24] Nonrandom “low” and 53 Daily Pred until remission; then alt Low dose same outcome as
“high” dose chlor- day Pred and chlorambucil ,3 high dose. 95% CT at 1 year
ambucil for fre- mg/kg/day (“low”) or .3.0 mg/kg/ 85% CR at 4 years. Steroid
quently-relapsing, day (“high”) resistant patients went in
steroid resistant NS CR for 1.3–9.4 years. Young
age most important
negative prognostic factor
APN [25] Steroid dependent NS 18 12 weeks Daily Pred until remission; then alt 67% sustained remission in 12
rx 12 weeks CTX day Pred and CTX 2 mg/kg/day week CTX; 22% sustained
compared retro to 18 8 weeks 3 12 weeks (historical CTX 2 mg/ remission in 8 weeks CTX
steroid dependent kg/day 3 8 weeks) (12 week group older and
cohort (APN, 1982) received more Pred)
rx 8 weeks CTX
Level 5 or 6
West [27] Review of experience 14 CTX 3–4 mg/kg/day with reduced Long-term remissions in
with CTX in NS doses of Pred steroid dependent and
frequently relapsing NS
Drummond [28] Observational study 12 CTX 75 mg/m2/day Long therapy with CTX (up to
12 months) decreased
relapse rate and associated
with clearing of proteinuria
in “steroid resistant” NS
Abbreviations are in Table 1.
receiving the standard regimen. Furthermore, fewer pa- further, or very rare, relapses. A relapse in the first six
tients with the long initial therapy ultimately became months was predictive of further relapses for the next
frequent relapsers [12]. Even though the total amount three years. Perhaps not surprisingly, the failure to
of prednisone taken for the first attack was greater than achieve remission in the first eight weeks of therapy
in the standard regimen, steroid side-effects were no predicted progression to renal failure in 21% of the chil-
more severe. The benefit was that less steroids were dren. The authors suggest that more aggressive therapy
subsequently taken because of the fewer relapses. A should be used to achieve remission in these children
similar result was found by investigators in Japan in who are slow to respond; however, it is possible that the
another level 1 study, in which children at first presenta- delayed or lack of response to standard therapy itself is
tion were randomized to either the ISKDC protocol or a marker for more aggressive disease [15].
a longer protocol involving a taper over five months. In summary, the intensity of initial therapy for minimal
Again, the longer treatment group had fewer relapses, lesion disease appears to determine the rate of subse-
and fewer of the patients became frequent relapsers. quent relapse and perhaps also the chances of becoming
Although the long-treatment group took more predni- a frequent relapser. The optimization point of initial
sone, the cumulative dose over the entire period of fol- dose of prednisone with its cumulative toxicity, versus
low-up was not different [13]. morbidity involved in relapse and its retreatment, ap-
The difficulty in determining the trade-off between a
pears to lie at an initial treatment with daily prednisone
cumulative steroid dose versus a relapse-free internal is
for four to six weeks and a course of alternate-day pred-well illustrated in a randomized ISKDC study that exam-
nisone for four to six weeks. Alternatively, a taperingined a long versus shorter steroid regimen in children who
course can be given over several months.had relapsed within six months of their initial response.
In this study, the long-treatment group received approxi- Treatment of relapse
mately twice as much prednisone as the other group, but
Recommendation 2. For patients with minimal lesionstayed in remission for a mean of 3.27 months compared
disease who relapse after initial treatment, prednisonewith 1.48 months. In the end, it was not clear, even to
should be given at 60 mg/m2 per day (up to 80 mg/day)many of the investigators, whether the extra steroid was
until the urine is protein free; then 40 mg/m2 should beworth the longer duration of remission [14].
given every other day for four weeks (grade A).A recent retrospective analysis of nearly 400 children
Evidence. Most children will have a relapse of theirwith minimal lesion disease found that if the children
nephrosis. The mean duration of corticosteroid therapyresponded to the first eight weeks of therapy with com-
to clear the urinary protein is similar for the relapseplete remission and maintained remission over the next
six months, the long-term outlook was excellent with no as for the initial attack [11]. However, the intensity of
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Table 3. Cyclosporine studies in children
Author [Ref] Study design N Treatment Results/comments
Level 1 or 2
Garin [48] Steroid-resistant NS (ML) 4 CsA 5 mg/kg/day 3 8 weeks No change in proteinuria with
Randomized or no treatment CsA; small #’s
crossover of CsA vs.
no treatment
Tejani [36] NS (1st episode in 50%) 6 CsA 1 Pred CsA 7 mg/kg/day 3 4 weeks 6/6 remission—duration of
randomized CsA 1 1 20 mg/m2 Pred then remission same as Pred
low dose Pred or high lower doses 3 4 weeks alone
dose Pred alone 7 Pred alone Pred 60 mg/m2/day 3 4weeks 6/7 remission
then alt day 3 4 weeks
Ponticelli [37] RCT CsA vs. CTX for 18 CsA 5–6 mg/kg/day 3 9 months 25% of CsA relapse free at 2
steroid-dependent then tapered 3 3 months years; 63% of CTX relapse
and frequently 13 CTX 1.5–2.5 mg/kg/day 3 8 free at 2 years. Adults same
relapsing NS weeks as children
Level 5 or 6
Niaudet [35] Multi-center ML: 45 CsA 150 mg/m2/day 1 Pred 23/45 CR or PR in minimal
uncontrolled study 30 mg/m2/day 3 4 weeks lesion group (? inadequate
CsA in “steroid then alt day. Total rx 6 initial Pred treatment—not
resistant” NS (Pred months really steroid resistant?)
3 4 weeks 1 3 pulses)
Gregory [50] Retrospective analysis ML: 3 CsA 5–10 mg/kg/day 1 2/3 maintain remission on
CsA in steroid- volume expansion in CsA alone; minimal
dependent and same; alt day Pred toxicity with long-term CsA
steroid-resistant NS monotherapy
Kitano [33] Frequent relapsers or 17 After remission, CsA 3–5 No relapses during CsA; all
steroid dependent rx mg/kg/day 3 6 months patients able to come off
CsA 3 6 months and then tapered Pred; but 40% relapsed by
1 month after CsA D/C’ed,
16/17 relapsed by one year
Tanaka [34] Frequent relapsers or 18 “High dose” CsA 3–5 mg/kg/ All patients able to come off
steroid dependent rx day 3 6 months, then 2.5 Pred; 8 growth, wt loss.
“high dose” CsA 3 6 mg/kg/day 3 12 months Marked 9 relapse rate
months then “low and then tapered. Also during CsA 7/18 relapse
dose” 3 12 months received Pred prn free 3 18 months, 14/18
relapsed within 6 months
of stopping CsA
Abbreviations are in Table 1.
prednisone treatment for a first relapse had no influence Treatment of frequently relapsing minimal
lesion diseaseon the subsequent relapse rate [14, 16].
The current relapse regimen consists of 60 mg/m2/day Recommendation 3. Patients with minimal lesion dis-
(up to 80 mg/day) of prednisone until the urine is free ease who relapse frequently should be treated with one
of protein for three days, followed by four weeks of of these regimens: cyclophosphamide or chlorambucil
alternate day prednisone at 40 mg/m2 [9]. This regimen for eight weeks (discussed in the text; grade A); repeat
is associated with fewer relapses in the first six months relapse therapy with prednisone (grade D); symptomatic
of treatment, compared with administering prednisone treatment only (Na restriction, diuretics; grade D); long-
three out of seven days in the second four weeks of term alternate-day prednisone (grade D); and/or levami-
therapy [8]. The ISKDC demonstrated that treating a sole (discussed in the text; grade B).
relapse for four weeks with daily prednisone rather than
Treatment of steroid-dependent minimaljust until the urine cleared of protein (average 12 days)
lesion diseasewas associated with a more prolonged remission (3.27
vs. 1.48 months) but at the cost of double the amount Recommendation 4. Children with steroid-dependent
of prednisone [14]. Because all patients in both groups minimal lesion disease should be treated with 2 mg/kg/
relapsed by eight months anyway, it is recommended to day of cyclophosphamide for 12 weeks (grade D) or 6
treat a relapse with daily prednisone only until the urine mg/kg/day of cyclosporine for children and 5 mg/kg/day
is protein free or for a few more days, and then proceed for adults, with the duration being uncertain (grade A).
with the tapering regimen as described earlier in this Evidence. Ten to 20% of children will experience
three or four steroid-sensitive attacks, and half will be-article.
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come frequent relapsers or steroid dependent. Given the low doses (less than 0.3 mg/kg/day) as effective as high
doses (more than 3.0 mg/kg/day) [23, 24]. The APN stud-cumulative toxicity associated with long-term corticoste-
roid therapy, treatment has evolved to include alkylating ied the effect of eight weeks of treatment with cyclophos-
phamide at 2 mg/kg/day versus chlorambucil at 0.15 mg/agents, antimetabolites, and cyclosporine in these more
difficult patient groups. A frequent relapser is a patient kg/day in 16 children with frequent relapsing and 34
children with steroid-dependent disease. In the frequentwho responds to corticosteroid treatment but experi-
ences two relapses within the first six months after the relapsers, the rate of relapse after treatment declined,
although actual rates of relapse prior to therapy wereinitial response or has four relapses within any one year
[17]. Up to one quarter of relapses in frequent relapsing not formally compared. In contrast, the eight weeks of
treatment did not apparently benefit the steroid-depen-minimal lesion may remit spontaneously [2]. Steroid de-
pendency is defined as two consecutive relapses oc- dent cohort, although once again, relapse rates were
not compared statistically before and after alkylatingcurring during therapy or within 14 days of completing
steroid therapy [16]. Therapeutic options for frequent therapy. There was no difference between chlorambucil
and cyclophosphamide, although the numbers wererelapsers include repeated relapse treatment with corti-
costeroid, prolonged tapering of alternate-day or daily small for that intergroup comparison [17]. In a subse-
quent prospective study, steroid-dependent patientssteroid, or symptomatic treatment with salt restriction
and diuretics. Unfortunately, there are no good studies (similar to the patients who failed the eight weeks of
alkylating therapy previously) were instead given 12to compare outcomes of these regimens. The repeated
or prolonged use of corticosteroids in either frequently weeks of therapy with 2 mg/kg/day of cyclophosphamide.
The 12 week group was compared retrospectively withrelapsing or steroid-dependent children carries with it
the risk of side-effects, including growth retardation, os- the steroid-dependent children who had received eight
weeks of cyclophosphamide. The cumulative rate of sus-teoporosis, obesity, and cataracts.
tained remission was 67% in the 12 week trial compared
with 22% in the 8 week trial. However, the children whoAntimetabolites and alkylating agents
received 12 weeks of cyclophosphamide were older thanThe ISKDC studied prednisone with placebo com-
the historical cohort, who received eight weeks, and maypared with prednisone and azathioprine for primary non-
have had a better prognosis because of this age differenceresponders and for frequent relapsers. This treatment
[25]. In contrast, a randomized controlled study fromhad no benefit for the steroid-resistant group (10 of
Japan comparing 8 versus 12 weeks of cyclophosphamidewhom ultimately showed focal sclerosis on renal biopsy)
head-to-head in steroid-dependent nephrotic syndromeor for the frequent relapsers [18].
found that 12 weeks did not confer any advantage. TheCyclophosphamide is more effective. A randomized
relapse rate was similar in both groups and similar tocontrolled trial in children with frequently relapsing min-
the eight-week treatment group of the APN [26]. Theimal lesion disease showed a statistically significant de-
better outcome with the 12 weeks may be confoundedcline in relapse rate in those given cyclophosphamide in
by the fact that the children were older and comparedaddition to prednisone, even though there were just 10
with historical controls.children in each group [19]. The same investigators then
Other retrospective or observational studies have con-compared two weeks of treatment and eight weeks of
firmed the effectiveness of cyclophosphamide in fre-treatment with cyclophosphamide in a randomized con-
quently relapsing or steroid-dependent nephrotic syn-trolled trial in frequent relapsers. Two weeks of cyclo-
drome [27–30].phosphamide led to more prolonged remission com-
pared with historical controls who received prednisone
Cyclosporinealone, whereas eight weeks of cyclophosphamide was
even more effective [20]. A level 1 ISKDC study of Very few of the studies of cyclosporine in pediatric
nephrosis are controlled, and most are small [31]. Thecyclophosphamide in frequent relapsers showed the clear
superiority of cyclophosphamide and prednisone (48% first such study, in the late 1980s, found that cyclosporine
treatment reduced relapses and total corticosteroid doserelapse after a mean of 22 months) compared with pred-
nisone alone (88% relapse after a mean of 22 months) [32]. Subsequent uncontrolled studies found complete
remissions in steroid-dependent or frequently relapsing[21]. Barratt et al extended their follow-up of cyclophos-
phamide in frequent relapsers to four years in a level 4 nephrotic syndrome, whereas many children were able
to stop corticosteroids [33, 34]. The largest study involvedstudy, which showed that the eight-week course con-
ferred a prolonged benefit to these patients [22]. 65 children with nephrotic syndrome, 45 of whom had
minimal lesion disease. These patients were classified asChlorambucil led to prolonged steroid-free remission
in children with frequently relapsing or steroid-depen- steroid resistant if they did not show remission after just
four weeks of daily corticosteroids followed by threedent (not steroid-resistant) nephrotic syndrome, with
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pulses of solumedrol. Of the 45 patients with minimal agents are as effective as cyclosporine and produce a
longer remission.lesion, 21 entered complete remission on cyclosporine
treatment in combination with prednisone. Seventeen of
these patients remained in remission after a mean three- Levamisole
year follow-up once stopping the cyclosporine, and most The antihelminthic agent levamisole has immunomod-
patients became steroid sensitive [35]. It may have been ulatory effects and has been used in a number of diseases,
premature, however, to classify these children as steroid such as cancer. Levamisole has been used alone or in
resistant after just four weeks of therapy. Some of the combination therapy in minimal lesion disease in chil-
patients who went into remission with cyclosporine may dren. Unfortunately, few of these studies were either
have actually been demonstrating a delayed response to randomized or controlled [39]. A level 5 study used 2.5
corticosteroid treatment. mg/kg twice weekly in frequently relapsing minimal le-
Most patients experience relapses of their disease sion disease. Half of the children had already received
when cyclosporine is tapered or discontinued, becoming other immunosuppressive agents besides prednisone,
cyclosporine dependent in the same way they were once which confuses the issue. Sixteen of the 30 patients stayed
steroid dependent [31]. Furthermore, with subsequent relapse free while on levamisole, but many relapsed
courses of cyclosporine treatment, the patients appear when it was stopped; however, the follow-up was short
to become progressively less responsive. [40]. A recent study from India used alternate-day leva-
In one of the few randomized studies, children in their misole therapy in steroid-dependent nephrotic syndrome
first year of nephrotic syndrome were randomized to once remission was obtained with corticosteroids. The
receive low-dose prednisone and cyclosporine or high- subsequent relapse rate decreased from a mean of 3 per
dose prednisone alone (in half of each group, this was year to 0.9 per year [41]. Other small studies found that
instituted with their first presentation). Children in treatment with levamisole induced or maintained remis-
both groups went into remission, and there was no differ- sion [42–44]. In one of only two controlled studies of
ence in the duration of remission once treatment was levamisole in pediatric nephrotic syndrome, an increased
stopped [36]. remission rate compared with placebo was found, but
When compared with alkylating agents, cyclosporine most children relapsed within three months of stopping
was not as successful in maintaining a prolonged remis- levamisole [45]. In the other controlled study, 21 of 33
sion in steroid-dependent nephrosis [31]. In a random- patients receiving levamisole were still in remission com-
ized controlled trial in both adults and children, cyclo- pared with 12 of 28 patients receiving no treatment, a
phosphamide and cyclosporine were equally successful nonsignificant difference [46].
in inducing remission in steroid-dependent and fre- Levamisole is well tolerated. The side effects noted
quently relapsing nephrotic syndrome. However, remis-
include neutropenia, rash, and liver toxicity [47]. How-
sions lasted longer in the group that received the alkylat-
ever, a review of the literature reveals no new large-
ing agent [37].
scale studies using this agent in nephrosis of children in
A recent uncontrolled retrospective study of the use
the last few years. Perhaps others find this agent lessof cyclosporine (2.5 to 5.0 mg/kg/day starting dose) in
effective than published trials suggest; otherwise, it issteroid-dependent and steroid-resistant nephrosis in chil-
unclear why this agent has not been more widely ac-dren (some of whom had focal sclerosis) reported good
cepted for this indication.results. There was halving of the steroid dependence in
the first group and restoration of steroid responsiveness
Treatment of steroid-resistant minimal lesion diseasein approximately one fourth of the patients in the latter
Recommendation 5. Management of steroid-resistantgroup. After a median follow-up of 7.5 years in the ste-
minimal lesion disease can include rebiopsy to rule outroid-dependent cohort and 5.0 years in the steroid-resis-
focal sclerosis (grade D), cyclophosphamide 2 mg/kg/tant group, there was no change in plasma creatinine
day 3 12 weeks (grade D), or cyclosporine at 6 mg/kg/daywith the exception of some of the patients with focal
for children or 5 mg/kg/day for adults for an uncertainsclerosis. A small number underwent follow-up renal
duration (grade D).biopsy, and striped interstitial fibrosis and tubular atro-
Evidence. Patients with steroid-resistant minimal le-phy were found, suggesting cyclosporine nephrotoxicity.
sion disease are the most difficult to treat. These patientsHowever, these were not accompanied by changes in
suffer the ill effects not only of corticosteroid toxicity,renal function (as judged by serum creatinine, though).
but of unremitting nephrosis with the attendant risks ofThe authors concluded that cyclosporine therapy in this
sepsis, malnutrition, growth retardation, and thrombosis.setting was effective adjunctive therapy with minimal
The patient with steroid-resistant nephrotic syndromelong-term nephrotoxicity [38].
also has a greater chance of progressive renal insuffi-In summary, for patients with steroid-dependent or
frequently relapsing minimal lesion disease, alkylating ciency culminating in end-stage renal disease.
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Studies in these children have been limited by small only in children, not in adults. The relapse rate was no
different between the methylprednisolone and the oralnumbers and short follow-up times. The only controlled
prednisone group. Corticosteroid-related side effectsstudy had eight children, four with minimal lesion and
were more prevalent in the group receiving oral predni-four with focal sclerosis. The patients received eight
sone. The investigators suggested that pulse methylpred-weeks of cyclosporine in a randomized cross-over design;
nisolone followed by low-dose oral prednisone was lessthere was no difference compared with no treatment [48].
effective than the usual regimen of high-dose oral ste-Given the paucity of evidence for cyclosporine, alkyl-
roid, but was associated with less corticosteroid-relatedating agents should be used first in children with fre-
side effects. In patients who are at risk for corticosteroidquently relapsing, steroid-dependent, and steroid-resis-
side effects (for example, adult patients with osteoporo-tant minimal lesion disease. Cyclosporine should be
sis), pulse steroid followed by low-dose oral prednisonereserved for those cases in which alkylating agents have
might be more appropriate compared with longer termfailed, especially in which there is unacceptable cortico-
high-dose oral steroid treatment. No studies have di-steroid toxicity and a holiday from prednisone is needed,
rectly addressed this question [51].to allow catch-up growth or puberty. Unfortunately,
An uncontrolled level 4 study of alternate-day cortico-most children continue to relapse when cyclosporine is
steroid treatment in adults with idiopathic nephrotic syn-withdrawn. The alternative, chronic cyclosporine ther-
drome used 60 to 120 mg of prednisone every other dayapy, carries the risk of nephrotoxicity, with the extent
for 9 to 12 months, followed by a gradual taper. Eighty-of damage to the kidneys out of proportion to the rise
three percent of patients with minimal lesion diseasein serum creatinine. Serial renal biopsies have been rec-
sustained a complete or partial remission. Although thisommended [49]. Progressive nephrotoxicity in children
regimen was effective, the prolonged duration of therapyon long-term cyclosporine therapy may be avoided if the
meant that the total amount of corticosteroids given waspatients are kept volume expanded, low doses are used,
at least as great as in patients receiving more conven-and levels are closely monitored [50].
tional therapy [52].
Antimetabolites and alkylating agentsTREATMENT OF MINIMAL LESION DISEASE
IN ADULTS Few studies have examined antimetabolites or alkylat-
ing agents in adults with minimal lesion disease. A level 5Corticosteroids
study of long-term azathioprine in patients with steroid-Few randomized controlled studies have examined the
resistant minimal lesion disease showed that all of thetreatment of adults with minimal lesion disease (Tables
patients had remission of their nephrotic syndrome and4 and 5). Observational studies from the 1950s showed
increased creatinine clearance by one year. Unfortu-rapid remissions after corticosteroid treatment of adult
nately, the patients had previously received very large
patients with minimal lesion disease. No controlled clini-
doses of steroids, and in this uncontrolled study, it is
cal trial was undertaken until 1970 when Black, Rose, unclear whether the remission was actually a late effect
and Brewer performed a multicenter controlled trial of of large doses of prednisone or whether this was just
steroid treatment in 125 adult nephrotic patients, includ- spontaneous remission [53].
ing 31 patients with biopsy-proven “minimal lesion” dis- Few studies have examined the use of cyclophospha-
ease (it is possible that patients with stage 1 membranous mide without corticosteroids in adult patients with mini-
glomerulonephritis could have been included in this mal change disease. In one study, 2 of the 10 patients
group) [3]. The treatment group received prednisone, at treated with cyclophosphamide alone went into remis-
least 20 mg/day, for at least six months, compared with sion [54]. In another study, very high doses of cyclophos-
a control group. In the patients with minimal lesion dis- phamide were used alone in a heterogeneous group of
ease, prednisone therapy gave an early and rapid de- eight patients with minimal lesion disease. Their gonadal
crease in proteinuria. Control patients showed a ten- status was not followed. In this study, nine weeks of
dency for remission of the proteinuria, although this therapy with this alkylating agent induced remission in
occurred much more slowly. By two and a half years, seven of these patients by five months. After a mean
the difference with respect to proteinuria and serum follow-up of six years, none of the patients relapsed.
albumin concentrations was not statistically significant Once again, however, this is a level 6 study, and it is
between the prednisone-treated and control group. difficult to make firm conclusions in a condition that has
Another multicenter randomized trial examined a tendency to remit if followed long enough [55].
whether adults and children with minimal lesion disease
Cyclosporinecould be more effectively treated with pulse methylpred-
nisolone compared with the usual treatment. The group Cyclosporine induces complete or partial remissions
in adults with minimal lesion disease. Two level 1 studiesreceiving methylprednisolone reached remission sooner
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Table 4. Corticosteroids and alkylating agents antimetabolites in studies of adults
Author [Ref] Study design N Treatment Results/comments
Level 1 or 2
Black [3] Multicenter RCT Pred 61 Pred Pred “not less than” 20 Early response in most ML Pred compared
20–30 mg/day .6 64 controls (31/ mg/kg/day 3 6 to controls; but gradual tendency to
months 125 had ML) months remission in ML controls over 2 years
Imbasciati Multicenter RCT children 67 children Solumedrol 20 mg/kg/i.v. Children receiving pulses had CR earlier
[51] 1 adults pulse IV daily 3 3, oral Pred 3 than oral Pred; no difference in adults.
methyl prednisolone vs. 22 adults 4 weeks, taper over 5 Tendency to earlier and more frequent
high dose oral Pred months relapses in pulse group; more steroid
vs. side effects in oral Pred group
Pred 60 mg/m2 or 1 mg/
kg/day 3 4 weeks, alt
Pred 3 5 months
Level 3 or 4
Bolton [52] Observational alt day 29 (ML) Pred 60–120 mg q alt day CR or PR in 83% of ML. Some also receive
steroids in different 3 9–12 months, then cytotoxics. Short F/U
GN’s taper
Nolasco [1] Retrospective review of 89 Pred 60 mg/day tapered Adults have lower 1 slower response to
adult onset ML (F/U of over 8 weeks; CTX (N Pred (?relatively lower dose c/w
Cameron 1974) 5 36) for initial rx, children), relapse less often, more stable
steroid “resistance” remission with CTX (66% remission at
or frequent relapses 5 years). Adults more 8 BP, ARF c/w
children. 6/8 no rx went into remission
slowly
Level 5 or 6
Sharpstone Observational Pred vs. 8 ML Pred 60 mg/day 3 3 days ML all started with Pred alone 6/8 CR. In
[76] Pred 1 AZA in tapered to 20 mg/day 2/8 changed to Pred 1 AZA—one
different primary GN’s 3 8 weeks; Pred 20 improved, one did not
mg/day 1 150 mg
AZA/day 3 8 weeks
Uldall [54] Observational CTX for 10 CTX 1.5 mg/kg/day, 2 patients received CTX only and went into
adult ML titrated to WBC CR; 8 patients had PR or relapses on
2.5–24 months Pred, on CTX all went into CR or near
CR. Alopecia and ovarian toxicity
Idelson [77] Review of steroid rx in 28 ML Corticosteroids (dose?) CR or PR predictive of long-term renal
various 1E adult GN’s outcome, also persistence of normal
renal function for at least 3 years
predictive of good outcome
Al-Khader Review of CTX alone for 8 CTX CTX 8 mg/kg body wt 7/8 CTX CR by 14 weeks (mean 10 weeks)
[55] “adult” ML (ages and tapered to WBC 2/8 diuretic only group CR
13–68) c/w diuretics 8 diuretics spontaneously by 12 months. None of 9
alone CR’s had relapses by 6 year F/U
Cade [53] Steroid-resistant ML 13 Pred 60 mg/day 3 4 All 13 showed 9 proteinuria, 8 CCr. All in
given AZA weeks, then very slow CR, but took up to one year to respond.
taper over months; if Effect of AZA or late effect of Pred?
failed rx or frequent
relapses that were
failing Pred changed to
AZA 2.0–2.5 mg/kg/
body wt 3 years
Lim [78] Idiopathic NS 11 ML Pred in various doses, 4/11 had spontaneous remission. Steroid
ACTH or no rx induced CR in 5
Abbreviations are in Table 1.
involving adults are multicenter studies from Italy. The of these steroid-resistant patients had focal sclerosis. Of
the two adults studied with minimal change disease, onefirst is a randomized controlled study in steroid-resistant
nephrotic syndrome comparing 5 mg/kg/day of cyclo- went into complete remission, and the other had no
response. The sample was too small to draw any conclu-sporine in adults and 6 mg/kg/day in children to placebo
[56]. Corticosteroid resistance was defined as persistence sion. Of the six children with minimal change disease,
four experienced reduction or remission of proteinuria,of nephrotic syndrome after six weeks of prednisone (1
mg/kg/day) for adults or five weeks of prednisone (60 mg/ and two had continuing nephrosis [56].
The other randomized, controlled trial involved pa-m2/day) for children. Unfortunately, eligibility included
focal sclerosis in addition to minimal lesion disease. Most tients with steroid-dependent (as opposed to steroid-
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Table 5. Cyclosporine in studies of adults
Author [Ref] Study design N Treatment Results/comments
Level 1 or 2
Ponticelli [37] See Table 3
(Children and Adults)
Level 3 or 4
Meyrier [61] CsA alone for GN with 29 ML CsA 5mg/kg/day; Pooled results: 72% chance of
steroid resistance or duration depended on remission with steroid
dependency response dependent ML Longest
CsA 1 Pred for Gn 29 ML CsA 5mg/kg/day tit- remission 12 months
with steroid rated to lower trough
resistance or levels and tapering
dependence Pred; duration
depended on response
Lee [62] Uncontrolled 22 ML (final) CsA up to 7 mg/kg/day up CR in 19/22; PR in 2/22
prospective study to 8 months; Pred 10 Failure in 1; relapses in 68%
steroid dependent or mg/kg/day by 10 months
resistant or frequent
relapsing NS
Level 5 or 6
Lagrue [57] Uncontrolled CsA for 10 ML CsA 3 mg/kg–5 mg/kg 3 CR in 7/10; PR in 2/10
steroid resistant or 3 months Failure in 1 (also steroid
dependent NS resistant). All relapsed
within 2–6 weeks
Maher [59] Uncontrolled CsA in 10 ML CsA 5–12 mg/kg/day for CR within 14 days. All
steroid dependent 40–230 days patients relapsed within
or resistant NS; some 1 IgM 180 days of discontinuation
failed CTX of CsA
Clasen [58] CsA for frequent 7 CsA 3–5 mg/kg BID and CR in 5/7. All relapsed with
relapsing or steroid tapered to blood tapering or
resistant ML levels. Pred tapered off discontinuation of CsA.
when therapeutic CsA Remission could be
levels reached reinduced with CsA. No
response in 2/7 up to 10
months
Green [60] NS resistant to Pred 6 3 ML CsA 6–10 mg/kg/day 3/3 CR within one month. All
CTX given CsA relapsed within 1–3 months
(details of prior rx of stopping CsA. Remission
not given) could be reinduced.
Abbreviations are in Table 1.
resistant) nephrotic syndrome or frequently relapsing [37]. Once again, however, it is important to emphasize
that there were only 11 adults altogether in this study.disease [37]. These patients were randomly allocated to
2.5 mg/kg/day of cyclophosphamide for eight weeks or Other uncontrolled studies in adults show results simi-
lar to those in children, that is, there is a good initial5 mg/kg/day of cyclosporine in adults (6 mg/kg/day in
children) for up to 12 months. Patients had to be in response [57] but a disheartening relapse rate as the drug
is tapered and discontinued [58–62].remission already, and prednisone was tapered off by
the first five weeks of the protocol. The majority of the In conclusion, the role of cyclosporine in minimal le-
sion disease may be (a) in frequently relapsing or steroid-patients were children (55 out of 64), but the results
were similar through all ages. Unlike the previous study, dependent disease, in which a trial of cyclophosphamide
has failed, (b) where cyclophosphamide is contraindi-the majority of patients had minimal lesion disease (31
out of 34). The population was similar to the ones in cated or there are concerns about gonadal toxicity, (c)
in steroid-dependent disease to allow a “steroid holiday”studies by the European and ISKDC groups discussed
earlier. As in those reports, cyclophosphamide was quite for catch-up growth and puberty, or (d) in steroid-resis-
tant disease.effective in producing a long-lasting remission. Two
years after treatment, 63% of the cyclophosphamide- Cyclosporine can produce long-term nephrotoxicity,
especially in adults whose underlying vascular disease istreated group were still in remission compared with 25%
of those treated with cyclosporine. The authors recom- more prevalent than in children. Patients with tubuloin-
terstitial lesions may progress to end-stage renal diseasemended that frequently relapsing or steroid-dependent
patients be treated with cyclophosphamide first. If that more rapidly when given this agent [61]. Without further
controlled studies, however, this interaction will be hardfails, then cyclosporine could be used as the next agent
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to tease out because the kind of nephrosis in which retrospective analyses, patients who develop acute renal
cyclosporine is often tried, such as steroid-resistant mini- failure are older, tend to be male, and are hypertensive
mal lesion disease or focal sclerosis, is in itself associated with evidence of vascular disease [63, 64]. A recent re-
with progression to renal failure. view of all reports in the English medical literature found
that the average age of patients with this complication
Long-term outcome of adults with minimal was 58 years. The mean urine protein excretion was 11.6
lesion disease g/day, and the patients had a mean serum albumin of
The long-term outcome of patients older than 15 has just 19 g/liter [65]. Acute renal failure occurred, on aver-
been examined retrospectively [1, 4]. Adults with mini- age, less than a month after onset of the nephrotic syn-
mal lesion disease, in contrast to children, have equal drome and lasted an average of seven weeks [65]. Despite
sex distribution. In addition, more of these adults had the prolonged course of renal failure, recovery almost
hypertension, and there was more microscopic hematu- always occurred. There is one report of five patients who
ria. Furthermore, adults show an increased prevalence did not recover renal function [66], but at least two of
of diminished glomerular filtration rate, and there was these patients probably had focal sclerosis. Many had
a significant mortality associated with this condition. In dye studies, and one patient refused dialysis and died
the Guy’s Hospital series of idiopathic nephrotic syn- (perhaps before renal function would have returned).
drome in adults, 25% had minimal lesion disease, show- On renal biopsy, patients with acute renal failure have
ing that this is a significant cause of idiopathic nephrotic more arteriosclerosis than those with preserved function
syndrome in adults. Five of the 49 patients presented [64]. Acute tubular necrosis is the most prevalent finding
with acute renal failure, and four of these needed dialysis but is not universally seen [64, 67]. Marked edema of
(acute renal failure in minimal lesion disease is discussed the tubulointerstitium has been described in some cases
later in this article) [4]. Three of the 49 patients had a [63] but is conspicuously absent in others [64].
spontaneous remission before therapy was given, sup- In the original descriptions of acute renal failure, it
porting the previous observation of Black, Rose, and was postulated that reduced plasma oncotic pressure led
Brewer [3]. Seventy percent of patients relapsed, most to a contracted plasma volume. With the added insults
them two or more times. This may have been related of vigorous diuresis or paracentesis, for example, the
to a shorter course of prednisone that they received kidneys became critically underperfused, and ischemic
compared with other studies. Complications of minimal acute tubular necrosis supervened [67].
lesion disease were similar to those seen in children, with This hypothesis has several weaknesses. As discussed,
the exception of acute renal failure. Three patients had
in patients with acute renal failure, acute tubular necrosispulmonary emboli, and two patients developed cellulitis.
is found on renal biopsy no more than 60 to 70% of theA follow-up study was published 12 years later of 89
time [64]. The duration of renal failure is atypically longpatients with a mean follow-up of 7.5 years [1]. Again,
for acute tubular necrosis, suggesting that other factorsthe prevalence of hypertension and microscopic hematu-
are contributing to the renal compromise.ria was confirmed. Glomerular filtration rate was dimin-
There is little compelling clinical evidence for markedished in 60% of patients. Patients who went into remis-
plasma volume depletion in patients who develop renalsion earlier also seemed to relapse earlier. In total, only
failure [65]. Indeed, the patients who develop renal fail-56% of patients were still protein free at nine months
ure have the highest blood pressures, compatible withand only 34% at two years. There was a much lower
the presence of vascular disease [64]. Plasma volume rep-relapse rate in these adults when they were given a course
letion does not reliably reverse the renal failure [65, 68].of cyclophosphamide. Sixty-three percent of the cyclo-
Improvement in techniques to measure plasma volumephosphamide-treated patients were still in remission
has led to the re-evaluation of the concept of plasmaafter 10 years of follow-up. These authors concluded that
volume contraction in the nephrotic syndrome. Plasmaadults had a lower and slower response to corticosteroids
volume in patients with minimal lesion disease appears(but were given proportionately less prednisone per
to be normal or even increased [69, 70]. The increasedbody weight compared with children). They sustained
rather than decreased plasma volume may be, in part, afewer relapses compared with children, and they seemed
result of a parallel fall in oncotic pressure in the intersti-to have a more stable and sustained remission after a
tial compartment of body water, which would decreasecourse of cyclophosphamide. Finally, hypertension, di-
flux of water out of the plasma compartment [71]. Fur-minished glomerular filtration rate, and acute renal fail-
thermore, renal excretion of salt and water is decreasedure were all more prevalent in the adult population.
in minimal lesion disease, which serves to keep the
Acute renal failure as a complication of minimal plasma compartment expanded [72, 73].
lesion disease Lowenstein, Schacht, and Baldwin noted the lack of
tubular necrosis in a retrospective review of 15 patientsA small subset of patients develop frank acute renal
failure as a complication of minimal lesion disease. In with minimal lesion disease complicated by acute renal
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bules and Bowman’s space, leading to a decreased glo-
merular filtration rate [63].
If there is convincing clinical evidence of plasma vol-
ume depletion in a given patient (decreased jugular ve-
nous pressure, hypotension), it may be reasonable to try
to normalize plasma volume with colloid, although this
may occur only transiently [74, 75]. Advocates of the
renal interstitial edema theory suggest diuretic treatment
sufficient to effect a vigorous diuresis [63]. However, it
is possible that the response to diuretics is simply a
marker of a functioning kidney, rather than a treatment
that restores function to an acutely failed kidney.
Recovery of renal function occurs in the majority of
patients. The duration of renal failure is typically pro-
longed, and the endogenous renal function should be
monitored while the patient is on dialysis.
SUMMARY
Among all of the glomerulonephritides in children,
minimal lesion disease is one of the most common. This
has made possible a large number of clinical trials, pro-
viding sufficient evidence for very clear treatment recom-
mendations (Fig. 1). Corticosteroid treatment is proven
effective in this group, although relapses occur. In adults,
however, a paucity of large randomized trials means that
recommendations cannot easily be made.
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